Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract

European Respiratory Journal

Volumn 14, Issue 1, 1999, Pages 221-229

  Wise, R ^a   Honeybourne, D ^b  

^a CITY HOSPITAL   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Fluoroquinolones; Lower respiratory tract infection; Pharmacodynamics; Pharmacokinetics; Tissue penetration

Indexed keywords

BETA LACTAMASE; CIPROFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; DRUG DISPOSITION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; ENZYME SYNTHESIS; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; ORAL DRUG ADMINISTRATION; PENICILLIN RESISTANCE; PHARMACODYNAMICS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; TISSUE LEVEL;

ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTIONS;

EID: 0032873185     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.1999.14a38.x     Document Type: Review

References (97)

1. Spangler SK, Jacobs MR, Pankuch GA, Appelbaum PC. Susceptibility of 170 penicillin-susceptible and penicillin-resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, RO 23-9424 and RP 7829. J Antimicrob Chemother 1993; 31: 273-280.
2. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418-1426.
3. European Study on Community-acquired Pneumonia Committee. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11: 986-991.
4. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Guidelines from the Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-838.
5. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77-83.
6. Doern GV. Trends in antimicrobial susceptibility of bacterial pathogens of the respiratory tract. Am J Med 1995; 99: 3S-7S.
7. Baquero F. Increasing role of resistance in LRTIs. Infect Med 1998; 15 (Suppl. 1): 16-27.
8. Macfarlane J, Prewett J, Rose D, et al. Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care. BMJ 1997; 315: 1206-1210.
9. Neu HC. Use of quinolones. Infect Dis Clin Pract 1992; 1: 1-10.
10. Brueggemann AB, Kugler KC, Doern GV. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 1997; 41: 1594-1597.
11. Bauernfeind A. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovefloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997; 40: 639-651.
12. Wiedemann B, Heisig P. Antibacterial activity of grepafloxacin. J Antimicrob Chemother 1997; 40 (Suppl. A): 19-25.
13. Sader HS, Erwin ME, Jones RN. In vitro antimicrobial activity of OPC-17116 compared to other broad spectrum fluoroquinolones. Eur J Clin Microbiol Infect Dis 1991; 11: 372-381.
14. Wise R, Andrews JM, Brenwald N. The in vitro activity of OPC-17116, a new 5-methyl substituted quinolone. J Antimicrob Chemother 1993; 31: 497-504.
15. Honeybourne D. The penetration of antimicrobial agents into lung tissue. Thorax 1994; 49: 104-106.
16. Stamey TA, Fair WR, Timothy MM. Serum versus urinary antimicrobial concentrations in cure of urinary tract infections. N Engl J Med 1974; 291: 1159-1163.
17. Baldwin DR, Wise R, Andrews JM, Honeybourne D. Quantitative morphology and water distribution of bronchial biopsy samples. Thorax 1992; 47: 504-507.
18. Efthymiopoulos C. Pharmacokinetics of grepafloxacin. J Antimicrob Chemother 1997; 40 (Suppl. A): 35-43.
19. Wise R, Mortiboy D, Child J, Andrews JM. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99, 219). Antimicrob Agents Chemother 1996; 40: 47-49.
20. Goa KL, Bryson HM, Markham A. Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections. Drugs 1997; 53: 700-725.
21. Nakashima M, Uematsu T, Kosuge K, et al. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob Agents Chemother 1995; 39: 2635-2640.
22. Echols R, Weinstein MP, O'Keeffe B, Shah A, Heller AH. Comparative crossover assessment of serum bactericidal activity and pharmacokinetics of ciprofloxacin and ofloxacin. J Antimicrob Chemother 1994; 33: 111-118.
23. Stone JW, Andrews JM, Ashby JP, Griggs D, Wise R. Pharmacokinetics and tissue penetration of orally administered lomefloxacin. Antimicrob Agents Chemother 1988; 32: 1508-1510.
24. Ritz M, Lode H, Fassbender M, Borner K, Koeppe P, Nord CE. Multiple-dose pharmacokinetics of sparfloxacin and its influence on fecal flora. Antimicrob Agents Chemother 1994; 38: 455-459.
25. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med 1989; 87 (Suppl. 6C): 31S-36S.
26. Wise R, Lockley R, Dent J, Webberly M. Pharmacokinetics and tissue penetration of enoxacin. Antimicrob Agents Chemother 1984; 26: 17-19.
27. Akiyama H, Koike M, Nu S, Ohguro K, Odomi M. OPC-17116, an excellently tissue-penetrative new quinolone: pharmacokinetic profiles in animals and antibacterial activities of metabolites. In: Program and Abstracts of the Thirty-First Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 1991. Abstract 1477. Washington, DC, American Society for Microbiology, 1991; pp. 38-39.
28. Wiebel ER. The ultrastructure of the alveolar-capillary barrier. In: Fishman AP, Hecht HH, eds. The Pulmonary Circulation and Interstitial Space. Chicago, The University of Chicago Press, 1969.
29. Staehelin LA. Structure and function of intracellular junctions. Int Rev Cytol 1974; 39: 283-287.
30. Williams MC. Conversion of lamellar body membranes into tubular myelin in alveoli of fetal rat lungs. J Cell Biol 1977; 72: 260-277.
31. Baldwin DR, Wise R, Andrews JM, Gill M, Honeybourne D. Comparative bronchoalveolar concentrations of ciprofloxacin and lomefloxacin following oral administration. Respir Med 1993; 87: 595-601.
32. Cook PJ, Andrews JM, Wise R, Honeybourne D, Moudgil H. Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. J Antimicrob Chemother 1995; 35: 317-326.
33. Andrews JM, Honeybourne D, Brenwald NP, et al. Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 39: 797-802.
34. Andrews JM, Honeybourne D, Jevons G, Brenwald NP, Cunningham B, Wise R. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1997; 40: 573-577.
35. Wise R, Honeybourne D. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J Antimicrob Chemother 1996; 37: 57-63.
36. Wise R, Honeybourne D. Antibiotic penetration into the respiratory tract. A basis for rational therapy. J Chemother 1995; 4: 28-32.
37. Tulkens PM. Intracellular distribution and activity of antibiotics. Eur J Clin Microbiol Infect Dis 1991; 10: 100-106.
38. Cook PJ, Andrews JM, Woodcock J, Wise R, Honeybourne D. Concentration of amoxycillin and clavulanate in lung compartments in adults without pulmonary infection. Thorax 1994; 49: 1134-1138.
39. Barry AL, Fuchs PC. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin. J Chemother 1997; 9: 9-16.
40. Eliopoulos GM. In vitro activity of fluoroquinolones against Gram-positive bacteria. Drugs 1995; 49 (Suppl. 2): 48-57.
41. Pankuch GA, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J Antimicrob Chemother 1995; 35: 230-232.
42. Wise R, Andrews JM, Ashby JP, Matthews RS. In vitro activity of lomefloxacin, a new quinolone antimicrobial agent, in comparison with those of other agents. Antimicrob Agents Chemother 1988; 32: 617-622.
43. Hoogkamp-Korstanje TAA. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pafloxacin, sparfloxacin and trovefloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections. J Antimicrob Chemother 1997; 40: 427-431.
44. Wise R, Andrews JM. The activity of grepafloxacin against respiratory pathogens in the UK. J Antimicrob Chemother 1997; 40 (Suppl. A): 27-30.
45. Barry AL. In vitro activities of OPC-17116 and five other fluoroquinolones. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 1992. Abstract 479.
46. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclonaphthyridone. Antimicrob Agents Chemother 1993; 37: 349-353.
47. Neu HC, Chin N-X. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 1994; 38: 2615-2622.
48. Neu HC, Chin N. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother 1989; 33: 1105-1107.
49. Roblin PM, Hammerschlag MR. Activity of a new quinolone BAY 12-8039 against C. pneumoniae in vitro. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstract F011.
50. Miyashita N, Niki Y, Kishimoto T, Nakajima M, Matsushima T. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 1331-1334.
51. Ishida K, Kaku M, Irifune K, et al. In vitro and in vivo activity of a new quinolones AM-1155 against Mycoplasma pneumoniae. J Antimicrob Chemother 1994; 34: 875-883.
52. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrob Agents Chemother 1993; 37: 1726-1727.
53. Kaku M, Ishida K, Irifune K, et al. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994; 38: 738-741.
54. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae and Ureaplasma urealyticum to a new quinolone, trovefloxacin (CP-99,219). Antimicrob Agents Chemother 1996; 40: 1048-1049.
55. Focht J. In vitro activity of BAY 12-8039 compared with other fluoroquinolones against bacterial strains from upper and lower respiratory tract infections in general practice. 2nd European Congress on Chemotherapy/7th BICON, 1998. Abstract T-161.
56. Ruckdeschel G, Lob S, Dalhoff A. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Legionella spp. in comparison to ciprofloxacin, erythromycin and rifampicin. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1996. Abstract F007.
57. Ridgway GL, Salman H, Robbins MJ, Dencer C, Felmingham D. The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. J Antimicrob Chemother 1997; 40 (Suppl. A): 31-34.
58. Dubois J, St-Pierre C. In vitro susceptibility study of grepafloxacin and five other antibiotics against Legionella species. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997; Abstract E30.
59. Roblin PM, Montalban G, Hammerschlag MR. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1402-1403.
60. Campos J, Roman F, Georgiou M, et al. Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis. J Infect Dis 1996; 174: 1345-1347.
61. Goldstein FW, Acar JF & The Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996; 38 (Suppl. A): 71-84.
62. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-160.
63. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP Ann Pharmacother 1991; 25: 1050-1057.
64. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. The pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
65. Hyatt JM, Nix DE, Schentag JJ, Pharmacokinetics and pharmacodynamics of ciprofloxacin against similar MIC strains of S. pneumoniae, S. aureus and P. aeruginosa using kill curve methodology. Antimicrob Agents Chemother 1994; 38: 2730-2737.
66. Nix DE, Schentag JJ. The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol 1988; 28:169-178.
67. Nix DE, Sands MF, Peloquin CA, et al. Dual individualization of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Am J Med 1987; 82 (Suppl. 4A): 352-356.
68. Grossman R, Mukherjee J, Vaughan D, et al, for the Canadian Ciprofloxacin Health Economic Study Group. A 1-year community-based health economic study of ciprofloxacin vs usual antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 1998; 113: 131-141.
69. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997; 40 (Suppl. A): 73-81.
70. Topkis S, Swarz H, Breisch SA, Maroli AN. Efficacy and safety of grepafloxacin, 600 mg q.d. for 10 days, in patients with community-acquired pneumonia. Clin Ther 1997; 19: 975-989.
71. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-1972.
72. Plouffe JF, Herbert MT, File TM Jr, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996; 40: 1175-1179.
73. Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin. Eur Respir J 1995; 8: 1999-2007.
74. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin versus ceftazidime in serious bacterial respiratory tract infections. Chest 1989; 96: 528-537.
75. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-470.
76. Davis R, Markham A, Balfour JA. Ciprofloxacin: an updated review of its pharmacology, therapeutic efficacy and tolerability. Drugs 1996; 51: 1019-1074.
77. Ferguson J, Dawe R. Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. J Antimicrob Chemother 1997; 40 (Suppl. A): 93-98.
78. Christ W, Esch B. Adverse reactions to fluoroquinolones in adults and children. Infect Dis Clin Pract 1994; 3 (Suppl. 3): S168-S176.
79. Jungst G, Mohr R. Overview of post-marketing experience with ofloxacin in Germany. J Antimicrob Chemother 1988; 22 (Suppl. C): 167-175.
80. Ball P, Tillotson G. Tolerability of fluoroquinolone antibiotics. Past, present and future. Drug Saf 1995 ; 13: 343-358.
81. Rubinstein E. Safety profile of sparfloxacin in the treatment of respiratory tract infections. J Antimicrob Chemother 1996; 37 (Suppl. A): 145-160.
82. Rizk E. The US clinical experience with lomefloxacin, a new once-daily fluoroquinolone. Am J Med 1992; 85 (Suppl. 4A): 130S-135S.
83. Jaillon P, Morgauroth J, Brumpt I, et al. Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. J Antimicrob Chemother 1996; 37 (Suppl. A): 161-167.
84. Trovan™ tablets and Trovan™ I.V., US Prescribing Information 1997; Pfizer Inc.
85. Furet YX, Pechere JC. Newly documented antimicrobial activity of quinolones. Eur J Clin Microbiol Infect Dis 1991; 10: 249-254.
86. Spangler S, Jacobs M, Appelbaum P. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, pipericillin, and pipericillint-azobactam against 489 anaerobes. Antimicrob Agents Chemother 1998; 38: 2471-2476.
87. Appelbaum P. Quinolone activity against anaerobes: microbiological aspects. Drugs 1995; 49 (Suppl. A): 76-80.
88. Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B. Torsades de pointes probably related to sparfloxacin. Eur J Clin Microbiol Infect Dis 1996; 15: 350-351.
89. Lee KL, Jim M-H, Tang SC, Tai Y-T. QT prolongation and torsade de pointes associated with clarithromycin. Am J Med 1998; 104: 395-396.
90. Freeman J, Platt R. Erythromycin prolongs the QTc interval among patients with pneumonia. Pharmacoepidemiol Drug Safety 1997; 6: 13-19.
91. Davis R, Bryson HM. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.
92. Efthymiopoulos C, Bramer SL, Maroli A, Blum B. Warfarin and theophylline interaction studies with grepafloxacin. Clin Pharmacokinet 1997; 33 (Suppl. 1): 39-46.
93. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
94. Honeybourne D, Baldwin D. The site concentrations of antimicrobial agents in the lung. J Antimicrob Chemother 1992; 30: 249-260.
95. Langan CE, Cranfield R, Breisch S, Pettit R. Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 (Suppl. A): 63-72.
96. Cooper B, Lawlor M. Pneumococcal bacteremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989; 87: 475.
97. Pan X-S, Fisher LM. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob Agents Chemother 1997; 45: 471-474.